Roberta Rudà1, Francesca Mo2, Alessia Pellerino2. 1. Department of Neuro-Oncology, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Turin, Italy. rudarob@hotmail.com. 2. Department of Neuro-Oncology, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Turin, Italy.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to highlight advances in the management of seizures in brain metastases from solid tumors. RECENT FINDINGS: The highest risk for seizures is in patients with melanoma and lung cancer. There is lack of data on the efficacy of antiepileptic drugs (AEDs), but interactions between enzyme-inducing AEDs and anticancer agents must be avoided. Levetiracetam and valproic acid are the most appropriate drugs. Prophylaxis with AEDs for patients with brain metastases without a history of seizures is not recommended. Total resection of a brain metastasis allows complete seizure control. Seizures may represent an adverse effect of stereotactic radiosurgery or of high-dose chemotherapy. New preclinical and clinical studies should define the risk of brain metastasis in light of the new treatment options in the different tumor types. New clinical trials should be designed in patients with brain metastases in terms of treatment or prophylaxis of seizures.
PURPOSE OF REVIEW: The purpose of this review is to highlight advances in the management of seizures in brain metastases from solid tumors. RECENT FINDINGS: The highest risk for seizures is in patients with melanoma and lung cancer. There is lack of data on the efficacy of antiepileptic drugs (AEDs), but interactions between enzyme-inducing AEDs and anticancer agents must be avoided. Levetiracetam and valproic acid are the most appropriate drugs. Prophylaxis with AEDs for patients with brain metastases without a history of seizures is not recommended. Total resection of a brain metastasis allows complete seizure control. Seizures may represent an adverse effect of stereotactic radiosurgery or of high-dose chemotherapy. New preclinical and clinical studies should define the risk of brain metastasis in light of the new treatment options in the different tumor types. New clinical trials should be designed in patients with brain metastases in terms of treatment or prophylaxis of seizures.
Authors: Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer Journal: Invest New Drugs Date: 2011-12-09 Impact factor: 3.850
Authors: Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: Peter A Forsyth; Susan Weaver; Dorcas Fulton; Penelope M A Brasher; Garnette Sutherland; Doug Stewart; Neil A Hagen; Penny Barnes; J Greg Cairncross; Lisa M DeAngelis Journal: Can J Neurol Sci Date: 2003-05 Impact factor: 2.104
Authors: John P Mongan; Camilo E Fadul; Bernard F Cole; Bassem I Zaki; Arief A Suriawinata; Gregory H Ripple; Tor D Tosteson; J Marc Pipas Journal: Clin Colorectal Cancer Date: 2009-03 Impact factor: 4.481
Authors: Tom Mikkelsen; Nina A Paleologos; Paula D Robinson; Mario Ammirati; David W Andrews; Anthony L Asher; Stuart H Burri; Charles S Cobbs; Laurie E Gaspar; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Jeffrey J Olson; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-03 Impact factor: 4.130
Authors: M Maschio; L Dinapoli; A Zarabla; A Pompili; C M Carapella; A Pace; D Giannarelli; E Occhipinti; B Jandolo Journal: J Neurooncol Date: 2007-06-28 Impact factor: 4.506
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Nayan Lamba; Paul J Catalano; Daniel N Cagney; Daphne A Haas-Kogan; Ellen J Bubrick; Patrick Y Wen; Ayal A Aizer Journal: Neurology Date: 2021-01-05 Impact factor: 9.910
Authors: María Martínez-García; Sonia Servitja Tormo; Noelia Vilariño Quintela; Ana Arance Fernández; Alfonso Berrocal Jaime; Blanca Cantos Sánchez de Ibargüen; Sonia Del Barco Berrón; Rosario García Campelo; Regina Gironés Sarrió; Juan Manuel Sepúlveda-Sánchez Journal: Clin Transl Oncol Date: 2022-03-08 Impact factor: 3.405
Authors: Stanisław Krajewski; Magdalena Wójcik; Marek Harat; Jacek Furtak Journal: Int J Environ Res Public Health Date: 2021-06-12 Impact factor: 3.390
Authors: Tobias Walbert; Rebecca A Harrison; David Schiff; Edward K Avila; Merry Chen; Padmaja Kandula; Jong Woo Lee; Emilie Le Rhun; Glen H J Stevens; Michael A Vogelbaum; Wolfgang Wick; Michael Weller; Patrick Y Wen; Elizabeth R Gerstner Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029